Antios Therapeutics宣布准予涵盖ATI-2173的美国专利申请的公告

StephenW

Antios Therapeutics Announces Notice of Allowance for a U.S. Patent Application Covering ATI-2173
ATLANTA, Feb. 24, 2020 /PRNewswire/ -- Antios Therapeutics, Inc. ("Antios"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. patent application No. 15/536,237, titled, "Phosphoramidates for the Treatment of Hepatitis B Virus," covering the composition of matter and methods of use for ATI-2173, a novel liver-targeted, orally-administered, small molecule against hepatitis B.

"We are pleased with the USPTO's Notice of Allowance as we continue the clinical development of this promising liver-targeted, non-chain terminating, HBV polymerase inhibitor," said co-founder and CEO, Abel De La Rosa, Ph.D.

This patent stems from research carried out at Emory University by Dr. De La Rosa and others during his tenure as Chief Scientific Officer of the Emory Institute for Drug Development (EIDD) and Drug Innovation Ventures at Emory (DRIVE). Antios has an exclusive worldwide license to ATI-2173 from DRIVE.

About ATI-2173

ATI-2173 is a novel liver-targeted molecule designed to deliver the 5'-monophosphate of clevudine. This L-nucleoside's active 5'-triphosphate has unique antiviral properties as a non-competitive, non-chain terminating HBV polymerase inhibitor. By selectively delivering the 5'-monophosphate to the liver, while retaining the unique anti-HBV activity of the active 5'- triphosphate, ATI-2173 could become an integral part of a curative combination regimen for chronic hepatitis B.

About Antios Therapeutics Inc.

Antios Therapeutics is a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases. Antios is currently developing ATI-2173, aiming to provide chronic hepatitis B infected patients with a curative combination regimen.

CONTACT: [email protected]

StephenW

Antios Therapeutics宣布准予涵盖ATI-2173的美国专利申请的公告
2020年2月24日，亚特兰大/ PRNewswire /-Antios Therapeutics，Inc.（以下简称“ Antios”）是一家临床阶段的生物制药公司，致力于开发治​​疗和治疗病毒性疾病的创新疗法，今天宣布，美国已商标局（USPTO）已发布美国专利申请第15 / 536,237号的许可通知，标题为“用于治疗乙型肝炎病毒的磷酸酰胺类”，涉及新型ATI-2173的物质组成和使用方法肝靶向的口服抗乙肝小分子。

联合创始人兼首席执行官Abel De La Rosa博士说：“随着我们继续这种有前途的肝脏靶向性，非链终止性HBV聚合酶抑制剂的临床开发，我们对USPTO的允许通知感到满意，”

该专利源自De La Rosa博士等人在埃默里大学进行的研究，他在任职期间担任埃默里药物开发研究所（EIDD）和埃默里药物创新风险投资公司（DRIVE）的首席科学官。 Antios从DRIVE获得ATI-2173的全球独家授权。

关于ATI-2173

ATI-2173是一种新型的肝靶向分子，设计用于递送克列夫定的5'-单磷酸酯。这种L-核苷的活性5'-三磷酸酯具有非竞争性，非链终止性HBV聚合酶抑制剂的独特抗病毒特性。通过将5'-单磷酸酯双重递送至肝脏，同时保留活性5'-三磷酸酯独特的抗HBV活性，ATI-2173可以成为慢性乙型肝炎治疗联合方案不可或缺的一部分。

关于Antios Therapeutics Inc.

Antios Therapeutics是一家临床阶段的生物制药公司，致力于开发治​​疗和治愈病毒性疾病的创新疗法。 Antios目前正在开发ATI-2173，旨在为慢性乙型肝炎感染患者提供治愈性联合治疗方案。

联系人：[email protected]

齐欢畅